Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Rating of “Buy” by Brokerages

Krystal Biotech, Inc. (NASDAQ:KRYS) has earned an average rating of “Buy” from the eight ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $202.29.

Several analysts have issued reports on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. HC Wainwright reissued a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a report on Tuesday, November 5th. Evercore ISI lifted their target price on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research note on Monday, August 12th. Stifel Nicolaus increased their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Finally, William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. This trade represents a 1.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Key Financial Inc purchased a new stake in shares of Krystal Biotech in the 2nd quarter valued at $28,000. GAMMA Investing LLC raised its position in Krystal Biotech by 160.3% in the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after purchasing an additional 93 shares in the last quarter. Blue Trust Inc. grew its position in shares of Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after buying an additional 163 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Krystal Biotech during the third quarter worth approximately $40,000. Finally, Values First Advisors Inc. acquired a new stake in Krystal Biotech in the third quarter valued at approximately $53,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock opened at $185.25 on Friday. The stock has a market capitalization of $5.33 billion, a P/E ratio of 104.66 and a beta of 0.80. The business has a 50 day simple moving average of $181.27 and a two-hundred day simple moving average of $184.40. Krystal Biotech has a 12 month low of $101.34 and a 12 month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. The company had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. Krystal Biotech’s quarterly revenue was up 879.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.67) EPS. As a group, research analysts anticipate that Krystal Biotech will post 2.97 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).